Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVX-ONCO-2 in Advanced Solid Tumors
NCT05071846Phase 1Active, not recruiting
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVX-ONCO-2 in solid tumor. Primary endpoint: Number of adverse events and/or serious adverse events at 6 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
MVX-ONCO-2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05071846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071846.